Fluicell publishes report for the first quarter 2022
Today, May 12 2022, Fluicell publishes the interim report for the period January 1 to March 31, 2022. The full report can be accessed through Fluicell’s investor relations page using or using the link provided below.
CEO Victoire Viannay comments:
“ On March 30 this year, Fluicell celebrated its tenth anniversary. This is a great source of pride for us and an important milestone for the company. My gratitude goes out to Gavin Jeffries, board member, CTO, and one of Fluicell’s founders, who has been a cornerstone of Fluicell’s development since the start, to our board of directors who have continuously supported our work, and to all present and past team members who have been contributing to what Fluicell is today. Together, we are looking forward to the next decade.
During the period, we have strengthened our team with great expertise in regenerative medicine and business development, launched our new technological innovation – Biopixlar AER, made significant progress in all our R&D collaborations and seen a significant increase in sales compared to last year. This shows that Fluicell is very active and well positioned with strong partners and products — ready to accelerate.”
Quarter 1 (January 1 – March 31) 2022 in summary
- Operating income amounted to KSEK 1,165 (901)
- Net sales of KSEK 843 (601)
- Operating profit before depreciation, EBITDA, amounted to KSEK -4,573 (-5,194)